ROR1-Specific VNAR Molecules for Solid-Tumor Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing ROR1-targeting therapies face challenges in generating high-affinity binding agents due to the high sequence identity between human, mouse, and rat ROR1, and ROR2 family members, and the large size of antibodies limits their penetration into solid tumors, making them ineffective for certain cancer treatments.
Innovation Solution
Development of ROR1-specific antigen binding molecules, such as immunoglobulin-like shark variable novel antigen receptors (VNARs), which are engineered to have specific CDR sequences and framework regions, allowing for high-affinity binding and improved tumor penetration through smaller, homodimeric structures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used to target ROR1, then high binding affinity can be achieved, but the large size of antibodies limits their penetration into solid tumors
Solution Approach 1:
The patent extracts only the essential antigen-binding variable domains (VNARs) from complete antibodies, creating smaller molecular entities that retain ROR1-specific binding capability while eliminating the size limitations of full-length antibodies. This allows improved penetration into solid tumors while maintaining target specificity.
Solution Approach 2:
The patent changes the molecular size parameter by transitioning from conventional antibody size to smaller VNAR fragments, while compensating for potential affinity losses through rational design of the variable domains and framework regions to optimize binding characteristics.
2Reliability
If conventional antibodies are engineered for high specificity to ROR1, then binding affinity improves, but the complexity of engineering increases due to high sequence identity between ROR1 and ROR2
Solution Approach 1:
The patent applies local quality by focusing engineering efforts on specific CDR regions (particularly CDR3) that provide discriminative binding to ROR1 versus ROR2, rather than attempting to engineer entire antibodies. This localized approach to affinity maturation reduces overall engineering complexity while achieving high specificity.
Solution Approach 2:
The patent segments the antibody into separate functional modules (VNAR variable domains with specific CDR sequences), allowing independent optimization of each domain's binding characteristics. This modular approach simplifies the engineering process by enabling focused mutagenesis and selection on individual domains rather than whole antibodies.
Data Source
AI summary
The present invention relates to receptor tyrosine kinase-like orphan receptor 1 (ROR1) specific variant antigen binding molecules and associated fusion proteins, chimeric antigen receptors, nucleic acid sequences, vectors, host cells, pharmaceutical compositions, medical uses and conjugates, and methods of preparing and using the same.